BSE filing, BSE: 543848. Summary written from the filing by ALFA Finder's alert engine.
Dev Labtech Venture Ltd: key numbers
- Share price
- ₹22.90
- Market cap
- ₹108.7 Cr
- Revenue (annual)
- ₹167.2 Cr
- Net profit (annual)
- ₹9.57 Cr
- P/E (TTM)
- 11.4×Sector 49.5×
- Promoter holding
- 56.69%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dev Labtech Venture Ltd
All →Dev Labtech Venture Convertible Warrants
Dev Labtech Venture will hold an EGM to approve the preferential issue of 1.37 crore convertible warrants, raising ₹17.81 Crore.
- Value
- ₹17.81 Cr
Dev Labtech Venture Capital Structure Change
Dev Labtech Venture Limited announced an increase in authorized share capital from 50 million to 62 million equity shares, each with a face value of Rs 5.
Dev Labtech Venture Fund Raise of ₹17.81 Cr
Dev Labtech Venture approved the preferential issue of 1.37 crore convertible warrants aggregating ₹17.81 crore. The company also increased its authorised share capital for future expansion.
- Value
- ₹17.81 Cr
Dev Labtech Venture Board Meeting Date
Dev Labtech Venture Ltd has scheduled a board meeting for October 7, 2026, to discuss raising funds via preferential allotment and increasing authorized share capital.
Dev Labtech Venture Annual General Meeting
Dev Labtech Venture Limited held its 33rd Annual General Meeting on September 26, 2026. Members considered the adoption of financial statements, director appointment, and related party transactions.
Dev Labtech Venture Debt & Borrowing: ₹2.1 Cr
Dev Labtech executed a ₹2.10 Cr working capital facility with HDFC Bank at 8.9% floating interest. The 12-month overdraft is secured against residential and commercial property.
- Value
- ₹2.10 Cr
- Execution
- 12 months, repayable on demand, subject to annual renewal
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.